programmable-mrna
(2)
Jacob Becraft
Jacob 'Jake' Becraft is the co-founder and CEO of Strand Therapeutics, a Boston biotech building the first programmable platform for mRNA medicines. Trained as a synthetic biologist at MIT, he helped invent what he calls a 'programming language for mRNA' - genetic circuits that let a drug make decisions inside the body, switching on only where and when it should. Strand's lead candidate, a self-replicating mRNA that instructs tumors to produce their own IL-12, delivered early complete responses in a first-in-human trial. Becraft has raised more than $400 million to chase the idea that programming biology will be as transformative for medicine as software was for computing.
Strand Therapeutics
Strand Therapeutics is a clinical-stage biotech building 'programmable' mRNA medicines - drugs engineered with logic circuits so they switch on the right protein, in the right cell, at the right time. Spun out of MIT in 2017 by synthetic biologists who wrote the first programming language for mRNA, Strand's lead candidate STX-001 is a self-replicating mRNA that makes tumors manufacture their own IL-12, turning cold cancers hot from the inside. Backed by Kinnevik, Regeneron, Amgen and Eli Lilly with over $250M raised.